Survival outcomes of patients with subglottic squamous cell carcinoma : a study of the National Cancer Database

• DOI: 10.1007/s00405-021-06712-w
• Publication Date: 2021-03-01T09:03:11Z
• Authors: Lucy L. Shi; Caitlin McMullen; Kathryn Vorwald; Anthony C. Nichols; S. Danielle MacNeil; J. Trad Wadsworth; Christine H. Chung; Xuefeng Wang; Krupal B. Patel
• Keywords: Squamous Cell Carcinoma of Head and Neck; Combined Modality Therapy; 3. Good health; Survival Rate; 03 medical and health sciences; 0302 clinical medicine; Head and Neck Neoplasms; Carcinoma, Squamous Cell; Humans; Laryngeal Neoplasms; Neoplasm Staging; Retrospective Studies

Subglottic squamous cell carcinoma (SCC) represents less than 5% of all laryngeal cancers. Our objective was to better characterize survival using the National Cancer Database (NCDB) registry from 2004 to 2015.403 patients met inclusion criteria. 63.8% presented with advanced-stage disease. Treatment regimens were as follows: 15.9% underwent surgery alone, 16.9% underwent surgery followed by adjuvant therapy, and 67.2% underwent primary chemo/radiation (C/RT). Five-year overall survival (OS) was 58.6% for Stage I and II patients, 49.1% for Stage III, and 36.3% for stage IV. Adjusted OS for all-stage patients was worse with C/RT compared to upfront surgery (40.6% vs. 58.4%; HR 1.83 [95%CI 1.29-2.61] p < 0.001) and adjusted OS for stage 4 disease was significantly worse with C/RT compared to surgery (26.0% vs. 45.2%, HR 1.79 [95%CI 1.17-2.73] p = 0.007).Majority of patients were treated with primary C/RT. Adjusted survival favors upfront surgery versus C/RT, especially in patients with Stage IV disease.